Rich Spano

PercuSurge, Inc. used to develop and market interventional embolic protection devices. It was a medical device company developing a new category of interventional cardiology products that are used in conjunction with the treatment of atherosclerosis or compromised arterial blood flow. It product, GuardWire Plus, was used in conjunction with conventional treatment such as balloon angioplasty and implantable stents, which is the key products used in treating compromised blood flow in the arteries of the human body. It was founded in 1995 and was headquartered in Sunnyvale, CA.

Keravision, Inc. was developed medical products for the treatment of common vision problems. The company was developed a new category of non-laser vision correction products for the treatment of common vision disorders, including myopia, hyperopia and astigmatism, to offer an alternative to eyeglasses, contact lenses and other vision correction surgical procedures. Its first product, Intacs corneal ring segments, based on its proprietary patented technology, has been approved by the FDA for correcting mild myopia. Intacs are the first surgical vision correction technology to be approved by the FDA for distribution and sales that is designed to permanently correct a patient's vision while providing the option of removability. Intacs are composed of two thin half-circles of polymer material that are inserted into the periphery of the cornea to reshape the curvature of the cornea to correct vision.

Abbott Cardiovascular Systems, Inc. manufactures medical devices. It also makes cardiac and peripheral vascular repair surgical systems. The company was founded in 1978 and is headquartered in Santa Clara, CA.

FlowCardia, Inc. designs, develops and manufactures endovascular devices. It offers flowmate Injector to optimize the performance of crosser cto recanalization and crosser catheter, a minimally-invasive endovascular device. The firm also provides portfolio of catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. The company was founded by Henry Nita and Erik T. Engelson in 2001 and is headquartered in Sunnyvale, CA.